1. Home
  2. GLSI vs EVC Comparison

GLSI vs EVC Comparison

Compare GLSI & EVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLSI
  • EVC
  • Stock Information
  • Founded
  • GLSI 2006
  • EVC 1996
  • Country
  • GLSI United States
  • EVC United States
  • Employees
  • GLSI N/A
  • EVC N/A
  • Industry
  • GLSI Biotechnology: Pharmaceutical Preparations
  • EVC Broadcasting
  • Sector
  • GLSI Health Care
  • EVC Industrials
  • Exchange
  • GLSI Nasdaq
  • EVC Nasdaq
  • Market Cap
  • GLSI 197.1M
  • EVC 205.2M
  • IPO Year
  • GLSI 2020
  • EVC 2000
  • Fundamental
  • Price
  • GLSI $14.39
  • EVC $2.47
  • Analyst Decision
  • GLSI Strong Buy
  • EVC Hold
  • Analyst Count
  • GLSI 1
  • EVC 1
  • Target Price
  • GLSI $38.00
  • EVC $1.75
  • AVG Volume (30 Days)
  • GLSI 23.6K
  • EVC 254.0K
  • Earning Date
  • GLSI 11-19-2024
  • EVC 11-06-2024
  • Dividend Yield
  • GLSI N/A
  • EVC 8.10%
  • EPS Growth
  • GLSI N/A
  • EVC N/A
  • EPS
  • GLSI N/A
  • EVC N/A
  • Revenue
  • GLSI N/A
  • EVC $1,146,066,000.00
  • Revenue This Year
  • GLSI N/A
  • EVC N/A
  • Revenue Next Year
  • GLSI N/A
  • EVC N/A
  • P/E Ratio
  • GLSI N/A
  • EVC N/A
  • Revenue Growth
  • GLSI N/A
  • EVC 60.94
  • 52 Week Low
  • GLSI $8.00
  • EVC $1.33
  • 52 Week High
  • GLSI $21.44
  • EVC $4.41
  • Technical
  • Relative Strength Index (RSI)
  • GLSI 55.04
  • EVC 62.15
  • Support Level
  • GLSI $11.89
  • EVC $2.16
  • Resistance Level
  • GLSI $13.79
  • EVC $2.59
  • Average True Range (ATR)
  • GLSI 0.74
  • EVC 0.11
  • MACD
  • GLSI 0.08
  • EVC 0.02
  • Stochastic Oscillator
  • GLSI 86.21
  • EVC 71.59

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.

About EVC Entravision Communications Corporation

Entravision Communications Corp is a global advertising solutions, media, and technology company. Its operations encompass integrated marketing and media solutions, comprised of television, radio, and digital properties and data analytics services. The company operates in television broadcasting, audio broadcasting, and digital media segments. The Company's digital segment, whose operations are located in Europe, Latin America, Asia, the United States, and Africa. The Company's television and audio operations reach and engage U.S. Hispanics in the United States.

Share on Social Networks: